vs

Side-by-side financial comparison of T1 Energy Inc. (TE) and VERACYTE, INC. (VCYT). Click either name above to swap in a different company.

T1 Energy Inc. is the larger business by last-quarter revenue ($210.5M vs $140.6M, roughly 1.5× VERACYTE, INC.). VERACYTE, INC. runs the higher net margin — 29.3% vs -62.0%, a 91.3% gap on every dollar of revenue. T1 Energy Inc. produced more free cash flow last quarter ($55.0M vs $48.8M).

Sony Energy Devices Corporation , is a Japanese multinational company specializing in a variety of areas in the energy industry, and is a wholly owned subsidiary and part of the Devices Group of Sony. The company was established in February 1975 in Fukushima, Japan.

Veracyte Inc. is a leading molecular diagnostics company that develops and commercializes proprietary genomic testing solutions for early, accurate detection of cancer and other complex diseases. Its offerings help healthcare providers make better clinical decisions to improve patient outcomes, with core operations in the U.S. and expanding global market presence across key clinical segments.

TE vs VCYT — Head-to-Head

Bigger by revenue
TE
TE
1.5× larger
TE
$210.5M
$140.6M
VCYT
Higher net margin
VCYT
VCYT
91.3% more per $
VCYT
29.3%
-62.0%
TE
More free cash flow
TE
TE
$6.2M more FCF
TE
$55.0M
$48.8M
VCYT

Income Statement — Q3 FY2025 vs Q4 FY2025

Metric
TE
TE
VCYT
VCYT
Revenue
$210.5M
$140.6M
Net Profit
$-130.6M
$41.1M
Gross Margin
10.0%
72.5%
Operating Margin
-45.0%
26.4%
Net Margin
-62.0%
29.3%
Revenue YoY
18.5%
Net Profit YoY
-375.2%
704.8%
EPS (diluted)
$-0.87
$0.50

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
TE
TE
VCYT
VCYT
Q4 25
$140.6M
Q3 25
$210.5M
$131.9M
Q2 25
$132.8M
$130.2M
Q1 25
$53.5M
$114.5M
Q4 24
$118.6M
Q3 24
$0
$115.9M
Q2 24
$0
$114.4M
Q1 24
$0
$96.8M
Net Profit
TE
TE
VCYT
VCYT
Q4 25
$41.1M
Q3 25
$-130.6M
$19.1M
Q2 25
$-31.9M
$-980.0K
Q1 25
$-16.2M
$7.0M
Q4 24
$5.1M
Q3 24
$-27.5M
$15.2M
Q2 24
$-27.0M
$5.7M
Q1 24
$-28.5M
$-1.9M
Gross Margin
TE
TE
VCYT
VCYT
Q4 25
72.5%
Q3 25
10.0%
69.2%
Q2 25
24.7%
69.0%
Q1 25
33.3%
69.5%
Q4 24
66.4%
Q3 24
68.2%
Q2 24
68.1%
Q1 24
64.5%
Operating Margin
TE
TE
VCYT
VCYT
Q4 25
26.4%
Q3 25
-45.0%
17.4%
Q2 25
-22.0%
-4.0%
Q1 25
-44.2%
2.5%
Q4 24
3.5%
Q3 24
10.4%
Q2 24
4.0%
Q1 24
-4.8%
Net Margin
TE
TE
VCYT
VCYT
Q4 25
29.3%
Q3 25
-62.0%
14.5%
Q2 25
-24.0%
-0.8%
Q1 25
-30.4%
6.2%
Q4 24
4.3%
Q3 24
13.1%
Q2 24
5.0%
Q1 24
-1.9%
EPS (diluted)
TE
TE
VCYT
VCYT
Q4 25
$0.50
Q3 25
$-0.87
$0.24
Q2 25
$-0.21
$-0.01
Q1 25
$-0.11
$0.09
Q4 24
$0.07
Q3 24
$-0.20
$0.19
Q2 24
$-0.19
$0.07
Q1 24
$-0.20
$-0.02

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
TE
TE
VCYT
VCYT
Cash + ST InvestmentsLiquidity on hand
$34.1M
$362.6M
Total DebtLower is stronger
$547.3M
Stockholders' EquityBook value
$96.9M
$1.3B
Total Assets
$1.4B
$1.4B
Debt / EquityLower = less leverage
5.65×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
TE
TE
VCYT
VCYT
Q4 25
$362.6M
Q3 25
$34.1M
$315.6M
Q2 25
$8.5M
$219.5M
Q1 25
$48.9M
$186.1M
Q4 24
$239.1M
Q3 24
$181.9M
$274.1M
Q2 24
$219.6M
$235.9M
Q1 24
$249.9M
$209.2M
Total Debt
TE
TE
VCYT
VCYT
Q4 25
Q3 25
$547.3M
Q2 25
$591.2M
Q1 25
$603.2M
Q4 24
Q3 24
Q2 24
Q1 24
$602.3M
Stockholders' Equity
TE
TE
VCYT
VCYT
Q4 25
$1.3B
Q3 25
$96.9M
$1.3B
Q2 25
$183.9M
$1.2B
Q1 25
$201.9M
$1.2B
Q4 24
$1.2B
Q3 24
$538.7M
$1.2B
Q2 24
$561.6M
$1.1B
Q1 24
$582.3M
$1.1B
Total Assets
TE
TE
VCYT
VCYT
Q4 25
$1.4B
Q3 25
$1.4B
$1.4B
Q2 25
$1.4B
$1.3B
Q1 25
$1.4B
$1.3B
Q4 24
$1.3B
Q3 24
$615.0M
$1.3B
Q2 24
$644.4M
$1.2B
Q1 24
$670.3M
$1.2B
Debt / Equity
TE
TE
VCYT
VCYT
Q4 25
Q3 25
5.65×
Q2 25
3.21×
Q1 25
2.99×
Q4 24
Q3 24
Q2 24
Q1 24
1.03×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
TE
TE
VCYT
VCYT
Operating Cash FlowLast quarter
$63.9M
$52.6M
Free Cash FlowOCF − Capex
$55.0M
$48.8M
FCF MarginFCF / Revenue
26.1%
34.7%
Capex IntensityCapex / Revenue
4.2%
2.7%
Cash ConversionOCF / Net Profit
1.28×
TTM Free Cash FlowTrailing 4 quarters
$-42.3M
$126.6M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
TE
TE
VCYT
VCYT
Q4 25
$52.6M
Q3 25
$63.9M
$44.8M
Q2 25
$33.4M
$33.6M
Q1 25
$-44.8M
$5.4M
Q4 24
$24.5M
Q3 24
$-28.4M
$30.0M
Q2 24
$-28.0M
$29.6M
Q1 24
$-16.2M
$-9.0M
Free Cash Flow
TE
TE
VCYT
VCYT
Q4 25
$48.8M
Q3 25
$55.0M
$42.0M
Q2 25
$10.6M
$32.3M
Q1 25
$-74.0M
$3.5M
Q4 24
$20.4M
Q3 24
$-34.0M
$27.7M
Q2 24
$-35.6M
$26.8M
Q1 24
$-37.7M
$-11.1M
FCF Margin
TE
TE
VCYT
VCYT
Q4 25
34.7%
Q3 25
26.1%
31.8%
Q2 25
8.0%
24.8%
Q1 25
-138.4%
3.1%
Q4 24
17.2%
Q3 24
23.9%
Q2 24
23.4%
Q1 24
-11.5%
Capex Intensity
TE
TE
VCYT
VCYT
Q4 25
2.7%
Q3 25
4.2%
2.1%
Q2 25
17.2%
1.0%
Q1 25
54.5%
1.6%
Q4 24
3.5%
Q3 24
1.9%
Q2 24
2.4%
Q1 24
2.2%
Cash Conversion
TE
TE
VCYT
VCYT
Q4 25
1.28×
Q3 25
2.34×
Q2 25
Q1 25
0.76×
Q4 24
4.80×
Q3 24
1.98×
Q2 24
5.16×
Q1 24

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

TE
TE

Related Party$120.1M57%
Nonrelated Party$90.4M43%

VCYT
VCYT

Testing$135.8M97%
Products$3.8M3%
Biopharmaceutical And Other$686.0K0%

Related Comparisons